Тёмный
No video :(

Amivantamab and Lazertinib in Patients with EGFR+ NSCLC - 2022 Program: Targeted Therapies Forum 

GRACE - Global Resource for Advancing Cancer Education
Просмотров 387
50% 1

Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Angel Qin looks at the Chrysalis-2 Trial, which studied the combination of Amivantamab and Lazertinib for EGFR+ NSCLC Patients with Progression on Osimertinib and platinum-based chemo.
We thank our sponsors for this year's support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech
For more, please visit cancerGRACE.org/.
To join the conversation, visit cancergrace.or....

Опубликовано:

 

14 авг 2024

Поделиться:

Ссылка:

Скачать:

Готовим ссылку...

Добавить в:

Мой плейлист
Посмотреть позже
Комментарии : 3   
@binebum1
@binebum1 Год назад
Excellent very clear thank you
@corgis7083
@corgis7083 2 месяца назад
Common names also in studies would help with communication with patience.
@CancergraceOrg
@CancergraceOrg 2 месяца назад
Yes, I agree. We encourage our faculty to use both generic and brand names which is a pretty easy thing to miss in a live webinar for our faculty who are accustom to using just one term. I'll pass your note along to our program manager and she may be able to correct this type of oversight in edit. Thanks for the input.
Далее
Муж на час 😂
00:37
Просмотров 931 тыс.
Atrial Fibrillation: New Solutions for an Old Problem
38:36
Approach to the Exam for Parkinson's Disease
18:46
Просмотров 1,2 млн
My Mom Died of Brain Cancer, And It Was Awful
2:33:00
Просмотров 16 тыс.
You Will NEVER Eat Sugar Again after This!
13:18
Просмотров 266 тыс.